Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule. This placebo and active controlled Phase 3 study is being conducted at 21 sites in the United States and will randomize approximately 250 patients to be treated for six months as follows: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients). With full enrollment in the study by early fourth quarter of this year, the results are expected to be available by late second quarter of 2011. This study is part of a registration-directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in the United States and Europe.
As previously announced, the National Institutes of Health (NIH) has awarded the company a two year $7.6 million Research and Research Infrastructure Grand Opportunities grant through the American Reinvestment and Recovery Act of 2009 (ARRA) which covers approximately half of the cost of this study, with the first year award of approximately $5.6 million available to Titan through September 2010. This grant is administered by the National Institute on Drug Abuse (NIDA).
"We are extremely pleased with the rapid progress being made towards completion of this confirmatory safety and efficacy study," said Dr. Katherine L. Beebe, Senior Vice President, Clinical Development and Medical Affairs, Titan Pharmaceuticals, and Principal Investigator of the study. "Thanks to the support for Probuphine by NIDA/NIH and the hard work of our investigators and their staff we are able to quickly advance the Probuphine Phase III clinical development program," she added.
Probuphine has the potential to reduce limitations currently associated with daily oral buprenorphine therapy, including poor compliance, morning withdrawal symptoms associated with variable blood levels and misdirection of drug. The safety and effectiveness of treatment with Probuphine has been initially established in the three Phase 3 studies conducted to date, specifically, a 163 patient placebo controlled study which demonstrated clinically meaningful and statistically significant treatment with Probuphine over a 24 week period, an open label 24 week retreatment study in 62 patients who had successfully completed six months of treatment in the controlled study, and a relative bioavailability study in 9 patients treated with Suboxone and then switched to Probuphine treatment for 60 days.
"These clinical sites have done an excellent job at recruiting and enrolling patients in our study, and we look forward to completing this confirmatory study in the second quarter of next year," said Sunil Bhonsle, President of Titan Pharmaceuticals.
The World Health Organization estimates that 2.8 million individuals in the U.S. and Europe are addicted to illicit opiates such as heroin, and more than 2.0 million individuals in the U.S. alone are addicted to prescription opioid medications. It is estimated that about twenty percent of this population are currently receiving pharmacological treatment.
"We are very encouraged with the progress of this important clinical study and believe that this is indicative of Probuphine's potential to serve unmet needs in the opioid addiction community for treatment alternatives," said Dr. Marc Rubin, Executive Chairman of Titan Pharmaceuticals.
Differential gene expression linked to alcohol use disorder, offering new treatment possibilities